3/24/2022 8:14:07 AM
Cyclo Enters Into Agreement With Wits Commercial Enterprise To Explore Potential Applications Of Trappsol Cyclo
12/6/2021 8:10:41 AM
Cyclo Receives IND Clearance From FDA To Advance Phase 2 Study Of Trappsol Cyclo For Treatment Of Alzheimer's Disease
11/16/2021 8:36:22 PM
Cyclo Therapeutics Prices Public Offering Of 1.95 Mln Shares At $6.00/shr
10/18/2021 8:09:56 AM
Cyclo Therapeutics Announces Abstract Accepted For Poster Presentation
8/17/2021 8:16:30 AM
Cyclo Therapeutics Q2 Net Loss $3.6 Mln Or $0.56/shr Vs. Loss $2.19 Mln Or $1.61/shr Prior Year
6/17/2021 8:13:04 AM
Cyclo Therapeutics Commences Patient Enrollment In Phase 3 Study Of Trappsol Cyclo In Niemann-Pick Type C1
5/11/2021 9:07:55 AM
Cyclo Therapeutics Names Lori McKenna Gorski Global Head Of Patient Advocacy
4/20/2021 9:28:31 AM
Cyclo Gets FDA Feedback Supporting Development Strategy To Submit IND Application For Phase 2 Study Of Trappsol Cyclo
3/25/2021 8:39:24 AM
Cyclo Therapeutics Meets Primary Efficacy Endpoint In Phase 1/2 Trial From Intravenous Trappsol Cyclo
3/10/2021 8:36:38 AM
Cyclo Therapeutics Names Russ Belden Acting Chief Commercial Officer
3/9/2021 9:09:39 AM
Cyclo Gets Positive Opinion From Paediatric Committee Of
EMA On Agreement Of PIP For Trappsol Cyclo
3/4/2021 9:14:07 AM
Cyclo Therapeutics Says Last Patient Completed Their Last Visit In The Phase 1/2 Study Evaluating Trappsol
2/9/2021 8:09:00 AM
Cyclo Therapeutics Presents Positive Data From Clinical Development Program For Trappsol Cyclo At WORLDSymposium 2021